Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Top Cited Papers
- 1 January 2008
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 9 (1), 45-53
- https://doi.org/10.1016/s1470-2045(07)70385-6
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast CarcinomaJournal of Clinical Oncology, 2007
- Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98Journal of Clinical Oncology, 2007
- Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?American Heart Journal, 2007
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004Journal of Clinical Oncology, 2005
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancerCancer, 2003
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002